Fixed Dose Combination
Fixed dose combinations refer to products containing two or more active ingredients used for a particular indication. Fixed Dose Combinations (FDCs) can be divided into the following groups and data required for approval for marketing is described below as per point no. 4 of second schedule of New Drugs and Cosmetics Rules, 2019 (NDCT) Rules, 2019:
(a) The first group of Fixed Dose Combinations (FDCs) includes those in which one or more of the active ingredients is a new drug. For such Fixed Dose Combinations (FDCs) to be approved for marketing data to be submitted will be similar to data required for any new drug (including clinical trials).
(b) (i) The second group Fixed Dose Combinations (FDCs) includes those in which active ingredients already approved or marketed individually are combined for the first time, for a particular claim and where the ingredients are likely to have significant interaction of a pharmacodynamic or pharmacokinetic nature. If clinical trials have been carried out with the Fixed Dose Combination (FDC) in other countries, reports of such trials should be submitted. If the Fixed Dose Combination (FDC) is marketed abroad, the regulatory status in other countries should be stated.
(ii) For marketing permission, appropriate chemical and pharmaceutical data will be submitted. In case such a combination is not marketed anywhere in the world but these drugs are already in use concomitantly (not as a Fixed Dose Combination (FDC) but individually) for the said claim, marketing permission may be granted based on chemical and pharmaceutical data. Data showing the stability of the proposed dosage form will also have to be submitted.
(iii) For any other such Fixed Dose Combinations (FDCs), clinical trials may be required. For obtaining permission to carry out clinical trials with such Fixed Dose Combinations (FDCs) a summary of available pharmacological, toxicological and clinical data on the individual ingredients should be submitted, along with the rationale for combining them in the proposed ratio. In addition, acute toxicity data (Lethal Dose 50 (LD 50)) and pharmacological data should be submitted on the individual ingredients as well as their combination in the proposed ratio.
(c) The third group of Fixed Dose Combinations (FDCs) includes those which are already marketed, but in which it is proposed either to change the ratio of active ingredients or to make a new therapeutic claim. For such Fixed Dose Combinations (FDCs), the appropriate rationale including published reports (if any) should be submitted to obtain marketing permission. Permission will be granted depending upon the nature of the claim and data submitted.
(d) The fourth group of Fixed Dose Combination (FDC) includes those whose individual active ingredients (or drugs from the same class) have been widely used in some particular indications for years, their concomitant use is often necessary and no claim is proposed to be made other than convenience. It will have to be demonstrated that the proposed dosage form is stable and the ingredients are unlikely to have significant interaction of a pharmacodynamic or pharmacokinetic nature. No additional animal or human data are generally required for these Fixed Dose Combinations (FDCs), and marketing permission may be granted if the Fixed Dose Combination (FDC) has an acceptable rationale.
Rules Governing Fixed Dose Combinations
The Rules are in accordance with the New Drugs and Clinical Trials Rules, 2019 of The Drugs and Cosmetics Act, 1940. The specific Rules are:
For conduct of Clinical Trial:
-
Rule 2(w): New Drug Definition
-
Rule 8: Registration of Ethics Committee relating to clinical trial, bioavailability and bioequivalence study.
-
Rule 21 – Application for permission to conduct clinical trial of a new drug or investigational new drug.
-
Rule 22 – Grant of permission to conduct clinical trial
-
Rule 23 – Permission to conduct clinical trial of a new drug or investigational new drug as part of discovery, research and manufacture in India
-
Rule 24 - Permission to conduct clinical trial of a new drug already approved outside India.
-
Rule 25 - Conditions of permission for conduct of clinical trial
-
Rule 26 - Validity period of permission to initiate a clinical trial
-
Rule 27 - Post-trial access of investigational new drug or new drug
-
Rule 29 - Inspection of premises relating to clinical trial
-
Rule 30 - Suspension or cancellation of permission to conduct clinical trial
-
Seventh Schedule: Formulae to Determine the Quantum of Compensation in The Cases of Clinical Trial Related Injury or Death
-
FDC Draft Guidelines -issued by CDSCO, Directorate General of Health Services, Govt. of India
For Import and Manufacture of new drugs for sale:
-
Rule 74-Regulation of new drug
-
Rule 75- Application for permission to import new drug for sale or distribution
-
Rule 76- Grant of permission for import of new drugs for sale or distribution
-
Rule 77- Condition of permission for import of new drugs for sale or distribution
-
Rule 78- Suspension or cancellation of import permission for new drug
-
Rule 79-Licence to import new drug for sale or for distribution under the Drugs and Cosmetics Rules, 1945
-
Rule 80- Application for permission to manufacture new drug for sale or distribution
-
Rule 81- Grant of permission for manufacture of new drug for sale or distribution
-
Rule 82- Condition of permission for manufacture of new drugs for sale or distribution
-
Rule 83-. Licence to manufacture a new drug for sale or for distribution under Drugs and Cosmetics Rules, 1945
-
Rule 84-Suspension or cancellation of permission
-
Rules 85- Responsibility of importers or manufacturers in marketing of new drugs
-
Rule 98- Pre-submission meeting
Functionalities
-
Processing of FDC applications (under category b to d) received for finished formulations approval, Additional dosage form, modified dosage form, Additional indication, additional strength and additional route of administration for the purpose of manufacture and marketing/ import and marketing in India as per the New Drugs and Clinical Trials Rules, 2019 under The Drugs and Cosmetics Act, 1940.
-
Processing of applications received for bioavailability or bioequivalence study, Clinical Trials (Phase II/III/IV) and active post marketing surveillance study as per the New Drugs and Clinical Trials Rules, 2019 under The Drugs and Cosmetics Act, 1940.
-
Data-base management (applications, receipts, e-office files and other misc. data)
-
Deliberation of proposals in expert committee meeting, SEC meeting, Technical Review Committee meeting, DCC meeting, DTAB meeting for evaluation of FDC applications.
-
Review/ Handling of complaints, parliament questions, Public Grievances and RTI queries related to Fixed Dose Combination.
-
Examine and processing the specific FDCs regarding their Ban, Restrict and prohibit the manufacture for sale, sale and distribution for human use of the said drug in the country.
-
Review and investigation regarding the complaints of manufacturing and marketing of unapproved FDC and cancellation of product permission issued by the SLA without due approval of DCG (I).
Currently there is no data available.

